Merck files Keytruda for MSI-H cancer
Merck & Co has filed its immunotherapy Keytruda in the US as a potential therapy for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer.
Read More
Tag: MSI-H cancer
- ErVimmune raises 17m euros in funding to develop cancer vaccine
- Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
